NCT06151808View on ClinicalTrials.gov

Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

November 28, 2023

Study Completion Date

January 10, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

XTR006

All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan

Trial Locations (1)

100089

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY